ATGC Co., Ltd. License Agreement Grants RELIFE S.r.l. Exclusive Rights to Register, Promote, Distribute, and Market the Novel Botulinum Toxin Type A (ATGC-100) in Europe and the United Kingdom.



- Implementation of Market Entry into Global Strategic Territories


ATGC Co., Ltd. (Jang, Sungsu, CEO of ATGC), a biopharmaceutical research and development company, has signed a strategic partnership, license and supply agreement with RELIFE S.r.l (Menarini Group) for ATGC-100 (Botulinum Toxin Type A, 900kDa) as part of its strategic entry into Europe and the United Kingdom.

ATGC Co., Ltd. announced today that it has signed a license agreement under which ATGC grants RELIFE S.r.l., part of the Menarini Group (the world’s largest Italian multinational biopharmaceutical company), exclusive rights to develop, register, promote, distribute, and market the novel botulinum toxin (BoNT) type A candidate ATGC-100 for medical aesthetic indications in selected strategic geographical areas.

“We are proud to announce that we have signed this exclusive licence agreement with RELIFE S.r.l., a company of the Menarini Group with a strong European and global presence, and this agreement marks a step forward for ATGC and the development of the novel botulinum toxin candidate ATGC-100”, commented Mr. Sung Su Jang, CEO of ATGC.

 “We are pleased to undertake this strategic partnership and agreement with ATGC, a company with years of dedication and experience in botulinum toxin development. We are confident that the longstanding commercial experience of Menarini Group as a trustworthy, reliable and strategic partner shall facilitate a successful product launch in the future. ATGC-100 will strengthen the comprehensive aesthetic medicine portfolio in RELIFE” commented by Mr. Silvester Sven Rossmann, Global Head of RELIFE S.r.l.

About botulinum toxin (BoNT)

Botulinum toxin (BoNT), neurotoxin produced by the Clostridium botulinum bacterium is a mainstay in the aesthetic and dermatologic armamentarium, with a well-known efficacy and safety profile, commonly used to treated rhytides (wrinkles) associated with ageing, it can be employed for a variety of other medical aesthetics or cosmetic purposes and medical disorders.

About ATGC Co., Ltd.

ATGC is an advanced biotechnology company, Korea-based research and development company with a pipeline of pharmaceutical development projects in preclinical and clinical phases. The Company develops ATGC-100, the novel botulinum toxin type A intended for medical aesthetic indications.


RELIFE S.r.l. is a Menarini Group company that believes in a patient-centred and science-based approach to medical aesthetics and clinical dermatology therapeutics. The vision of RELIFE is to become a world leading research-based aesthetic medicine and dermatology company.


Our values

Our values

Everyday we put our values into action. 4 values, which have given life to Menarini and have shaped its history.

Read More

Our values

Follow our blog

Discover our stories from all over the world

Read More